SARS-CoV-2 and the safety margins of cell-based biological medicinal products
Jens Modrof, Astrid Kerschbaum, Maria R. Farcet, Daniela Niemeyer, Victor M. Corman, Thomas R. Kreil
Abstract
With the pandemic emergence of SARS-CoV-2, the exposure of cell substrates used for manufacturing of medicines has become a possibility. Cell lines used in biomanufacturing were thus evaluated for their SARS-CoV-2 susceptibility, and the detection of SARS-CoV-2 in culture supernatants by routine adventitious virus testing of fermenter harvest tested.
Topics & Concepts
BiomanufacturingVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicCoronavirus disease 2019 (COVID-19)Industrial fermentation2019-20 coronavirus outbreakVirusBiologyCell cultureBiotechnologyMedicineFood scienceFermentationInfectious disease (medical specialty)OutbreakDiseasePathologyGeneticsBiomedical and Engineering EducationSARS-CoV-2 and COVID-19 ResearchViral Infectious Diseases and Gene Expression in Insects